In:
Dementia and Geriatric Cognitive Disorders, S. Karger AG, Vol. 31, No. 6 ( 2011), p. 413-416
Abstract:
〈 i 〉 Background/Aims: 〈 /i 〉 Detection and differentiation of neurodegenerative dementias, such as dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD), with blood-based biomarkers would facilitate diagnosis and treatment. 〈 i 〉 Methods: 〈 /i 〉 By use of a commercially available ELISA kit, we measured α-synuclein levels in the serum of 40 DLB patients and controls, and of 80 AD patients. 〈 i 〉 Results: 〈 /i 〉 We found significantly reduced α-synuclein serum levels in DLB compared to both AD (p = 0.006) and control subjects (p = 0.001), reaching an area under the curve of 〉 0.70. 〈 i 〉 Conclusion: 〈 /i 〉 Although these results do not justify a definition of serum α-synuclein as a potential single biomarker, results may contribute to a multimarker strategy in DLB diagnosis.
Type of Medium:
Online Resource
ISSN:
1420-8008
,
1421-9824
Language:
English
Publisher:
S. Karger AG
Publication Date:
2011
detail.hit.zdb_id:
1482186-2
Permalink